Apremilast

Category: pharmacological

Aliases: Otezla

Pharmacological Mechanism

PDE4 inhibitor — raises cellular cAMP → reduced inflammatory cytokine release. Oral approval for psoriasis + psoriatic arthritis + Behçet syndrome. Modest efficacy + cleaner side-effect profile (no infection / malignancy risk) than biologics.

Half-Life (t½)

PO: 8h

Dosing Guidelines

• PO: Typical 30mg (Range: 10 - 30 mg)

Target Organ Systems

• integumentary
• immune-hematologic